Indication
Relapsed/Refractory Follicular Lymphoma With EZH2
1 clinical trial
1 product
Product
TazemetostatClinical trial
A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Tazemetostat for the Treatment of Patients With Relapsed/Refractory Follicular LymphomaStatus: Recruiting, Estimated PCD: 2023-06-01